10299 Results for "

cancer,

" in MedChemExpress (MCE) Product Catalog:
Products (10299)

10299 Results for "cancer," in MCE Product Catalog:

1221
1221 Publications Verification
Cat. No.: HY-10108A
CAS No.: 934389-88-5
Purity:  99.93%
Research Areas:  

Cancer

LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
loading...
    loading...
859
859 Cited Publications
Cat. No.: HY-17394
CAS No.: 15663-27-1
Synonyms: cis-Platinum; CDDP; cis-Diaminodichloroplatinum
Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
loading...
    loading...
644
644 Cited Publications
Cat. No.: HY-100523
CAS No.: 846557-71-9
Purity:  99.96%
ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .
loading...
    loading...
627
627 Cited Publications
Cat. No.: HY-12041
CAS No.: 129-56-6
Purity:  99.73%
Research Areas:  

Cancer

SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
loading...
    loading...
573
573 Cited Publications
Cat. No.: HY-100218A
CAS No.: 1219810-16-8
Purity:  99.90%
Synonyms: (1S,3R)-RSL3
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
loading...
    loading...
300
300 Cited Publications
Cat. No.: HY-17026
CAS No.: 95058-81-4
Synonyms: LY 188011
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer .
loading...
    loading...
262
262 Cited Publications
Cat. No.: HY-15654
CAS No.: 1716-12-7
Purity:  99.86%
Synonyms: 4-PBA sodium; 4-Phenylbutyric acid sodium; Benzenebutyric acid sodium
Target:  

HDAC Autophagy Apoptosis

Research Areas:  

Cancer

Sodium 4-phenylbutyrate (4-PBA sodium) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research .
loading...
    loading...
262
262 Cited Publications
Cat. No.: HY-A0281
CAS No.: 1821-12-1
Synonyms: 4-PBA; Benzenebutyric acid
Target:  

HDAC Virus Protease

Research Areas:  

Infection Cancer

4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.
loading...
    loading...
255
255 Cited Publications
Cat. No.: HY-50767
CAS No.: 571190-30-2
Synonyms: PD 0332991
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
255
255 Cited Publications
Cat. No.: HY-50767A
CAS No.: 827022-32-2
Synonyms: PD 0332991 monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
251
251 Cited Publications
Cat. No.: HY-A0065
CAS No.: 827022-33-3
Synonyms: PD 0332991 isethionate
Target:  

CDK

Research Areas:  

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
236
236 Cited Publications
Cat. No.: HY-17371
CAS No.: 61825-94-3
Research Areas:  

Inflammation/Immunology Cancer

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .
loading...
    loading...
235
235 Cited Publications
Cat. No.: HY-50767C
CAS No.: 571189-11-2
Synonyms: PD-0332991 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
222
222 Cited Publications
Cat. No.: HY-50895
CAS No.: 184475-35-2
Synonyms: ZD1839
Target:  

EGFR Autophagy Apoptosis

Research Areas:  

Infection Metabolic Disease Cancer

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
loading...
    loading...
209
209 Cited Publications
Cat. No.: HY-15147
CAS No.: 284028-89-3
Purity:  99.80%
Target:  

β-catenin PARP

Research Areas:  

Cancer

XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
loading...
    loading...
208
208 Cited Publications
Cat. No.: HY-15772
CAS No.: 1421373-65-0
Purity:  99.92%
Synonyms: AZD-9291; Mereletinib
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
208
208 Cited Publications
Cat. No.: HY-15772A
CAS No.: 1421373-66-1
Purity:  99.97%
Synonyms: AZD-9291 mesylate; Mereletinib mesylate
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
197
197 Cited Publications
Cat. No.: HY-W008923
CAS No.: 17086-28-1
Doxycycline monohydrate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline monohydrate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline monohydrate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline monohydrate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline monohydrate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline monohydrate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .
loading...
    loading...
191
191 Cited Publications
Cat. No.: HY-13629
CAS No.: 33419-42-0
Purity:  99.94%
Synonyms: VP-16; VP-16-213
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .
loading...
    loading...
180
180 Cited Publications
Cat. No.: HY-A0098
CAS No.: 11089-65-9
Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits N-linked glycosylation and blocks GlcNAc phosphotransferase (GPT). Tunicamycin causes accumulation of unfolded proteins in cell endoplasmic reticulum (ER) and induces ER stress, and causes blocking of DNA synthesis and cell cycle arrest in G1 phase. Tunicamycin inhibits gram-positive bacteria, yeasts, fungi, and viruses and has anti-cancer activity .Tunicamycin increases exosome release in cervical cancer cells .
loading...
    loading...